Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL

Video

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

The FDA has approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed or refractory NHL, based on complete remission (CR) rates in the phase II ZUMA-1 trial.

In the single-arm ZUMA-1 study, axi-cel demonstrated an objective response rate (ORR) of 82% and a CR rate of 54%. After 8.7 months of follow-up, 39% of patients remained in CR. The median duration of response in those with a CR was not reached at the time of assessment (95% CI, 8.1-not estimable). The label for the medication lists the ORR as 72% and the CR rate as 51% (95% CI, 41%-62%).

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD